In the former, there are three entities: (1) MDSs with low blasts and 5q deletion (MDS-5q); (2) MDSs with low blasts and SF3B1 mutation (MDS- SF3B1); and (3) MDSs with biallelic TP53 inactivation (MDS-biTP53). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.